Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.

Autor: Yeni P (AUTHOR), Cooper DA (AUTHOR), Aboulker J (AUTHOR), Babiker AG (AUTHOR), Carey D (AUTHOR), Darbyshire JH (AUTHOR), Floridia M (AUTHOR), Girard P (AUTHOR), Goodall RL (AUTHOR), Hooker MH (AUTHOR), Mijch A (AUTHOR), Meiffredy V (AUTHOR), Salzberger B (AUTHOR), INITIO Trial International Co-ordinating Committee (CORPORATE AUTHOR)

Publikováno v: Lancet. 7/22/2006, Vol. 368 Issue 9532, p287-298. 12p.